Showing results (261-270 of 282) with videos related to

Sort By:
Pageof 29
Bioorganic & Medicinal Chemistry Letters|May 22, 2009
Design and optimization of renin inhibitors: Orally bioavailable alkyl aminesColin M Tice, Zhenrong Xu, Jing Yuan, et al.
Digital Biomarkers|October 21, 2020
Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure TrialsFrank Kramer, Javed Butler, Sanjiv J Shah, et al.
Human Mutation|February 18, 2021
The phenotypic and genetic spectrum of patients with heterozygous mutations in cyclin M2 (CNNM2)Gijs A C Franken, Dominik Müller, Cyril Mignot, et al.
Transplantation|April 30, 2024
Favorable Outcome After Single-kidney Transplantation From Small Donors in Children: A Match-controlled CERTAIN Registry StudyRaphael Schild, Karla Carvajal Abreu, Anja Büscher, et al.
Circulation. Heart Failure|May 12, 2016
Developing New Treatments for Heart Failure: Focus on the HeartMihai Gheorghiade, Christopher J Larson, Sanjiv J Shah, et al.
Journal of the American Society of Nephrology : JASN|August 19, 2022
Inflammation in Children with CKD Linked to Gut Dysbiosis and Metabolite ImbalanceJohannes Holle, Hendrik Bartolomaeus, Ulrike Löber, et al.
Kidney International Reports|October 27, 2025
Novel RRAGD Variants in Autosomal Dominant Kidney Hypomagnesemia and Therapeutic PerspectivesAnastasia Adella, François Jouret, Leire Madariaga, et al.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 31, 2015
Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1Anja Lehnhardt, Claartje Karnatz, Thurid Ahlenstiel-Grunow, et al.
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Pageof 29